Hagit Tulchinsky, MD, 1,2 Einat Shmueli, MD, 3 Arie Figer, MD, 3 Joseph M. Klausner, MD, 2 and Micha Rabau, MD 1,2
|
|
- Tamsin Campbell
- 5 years ago
- Views:
Transcription
1 Annals of Surgical Oncology DOI: /s An Interval [7 Weeks between Neoadjuvant Therapy and Surgery Improves Pathologic Complete Response and Disease Free Survival in Patients with Locally Advanced Rectal Cancer Hagit Tulchinsky, MD, 1,2 Einat Shmueli, MD, 3 Arie Figer, MD, 3 Joseph M. Klausner, MD, 2 and Micha Rabau, MD 1,2 1 Proctology Unit, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 2 Department of Surgery B, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 3 Department of Oncology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Background: We assessed whether the time interval between neoadjuvant therapy and surgery affects the operative and postoperative morbidity and mortality, the pathologic complete response (pcr) rate, and disease recurrence in locally advanced rectal cancer. Methods: One hundred and thirty-two patients with locally advanced low and mid rectal cancer underwent neoadjuvant chemoradiation followed by radical resection (October 2000 to December 2006). Data on the neoadjuvant regime, neoadjuvant surgery interval, final pathology, type of operation, operative time, intraoperative blood transfusions, postoperative complications, length of hospital stay, disease recurrence, and mortality were reviewed. The patients were divided into two groups according to the neoadjuvant surgery interval: 7 weeks (group A, n = 48), and [7 weeks (group B, n = 84). Results: The groups were demographically comparable except for the group A patients being younger at operation. The median interval between chemoradiation and surgery was 56 days (range days). Thirty-seven patients (28%) had a pcr and near pcr. Fifty three patients (40%) had complications. There was no in-hospital mortality. Surgery type, operative time, number of intraoperative blood transfusions, postoperative complications, and length of hospitalization were not influenced by the interval length. The pcr and near pcr rates were higher with longer interval: 17% in group A, 35% in group B (P = 0.03). Patients operated at an interval [7 weeks had significantly better disease free survival (P = 0.05). Conclusions: A neoadjuvant surgery interval [7 weeks was associated with higher rates of pcr and near pcr, decreased recurrence and improved disease free survival. Key Words: Rectal cancer Preoperative chemoradiation Neoadjuvant Interval. Address correspondence and reprint requests to: Hagit Tulchinsky, MD; hagitt@tasmc.health.gov.il Published by Springer Science+Business Media, LLC Ó 2008 The Society of Surgical Oncology, Inc. Preoperative neoadjuvant chemoradiation as an adjunct to surgery for locally advanced mid and low rectal cancer has been shown to achieve pathologic downstaging, with improvement of resectability and sphincter saving surgery, in addition to improving local control. 1 4 The optimal time interval between completion of neoadjuvant treatment and performing surgery (the neoadjuvant surgery interval) is still indefinite. Few studies have looked at the influence of the length of the neoadjuvant surgery interval on morbidity, resectability, and tumor response. 5 8 One of them, by Francois et al., 5 showed
2 H. TULCHINSKY ET AL. that an interval of 6 8 weeks provided increased tumor downstaging when compared to a 2 week interval. The purpose of the current study was to assess the influence of different neoadjuvant surgery intervals on the following parameters: perioperative morbidity and mortality, tumor pathologic complete response (pcr), disease free survival (DFS), and overall survival (OS). METHODS We performed a retrospective review of a prospectively entered database on 146 consecutive patients with biopsy proven locally advanced (T3-4 or N1 and/or clinically bulky) low (at or below 5 cm from the anal verge) and mid (6 11 cm from the anal verge) rectal adenocarcinoma who underwent neoadjuvant therapy followed by radical resection with total mesorectal excision (TME) for curative intent between October 2000 and December The examined parameters included the neoadjuvant regime, the neoadjuvant surgery interval, the type of operation, operative time, intraoperative blood transfusions, postoperative complications (minor and major, operation related and none related), length of hospital stay, and mortality. Pathologic reports were reviewed to assess the tumor node metastasis (TNM) staging and the pcr and near pcr rates (the latter being defined by the finding of microscopic foci of adenocarcinoma in the rectal wall with no cancer cells in the lymph nodes). Fourteen patients were excluded from analysis: liver metastases were found at operation in two, two underwent an R2 resection, one had a pelvic exenteration, three were lost to follow-up and 6 patients received only radiation as neoadjuvant. The remaining 132 patients compose the study population. Patients were divided into two groups according to the neoadjuvant surgery interval: 7 weeks (group A) and [7 weeks (group B). The pre-treatment staging was based on rigid rectoscopy for localization of the tumor in the rectum, endorectal ultrasonography (EUS), and computerized tomography (CT) of the pelvis for local tumor status, abdominal CT, chest X-ray, and/or chest CT to rule out distant metastases. The neoadjuvant regimen included high dose radiation therapy of Gy, usually with concomitant 5-fluorouracil (FU) based chemotherapy. Radiotherapy was administered 5 days per week for 5.5 weeks. Patients were treated with 5-FU either in continuous infusion (180 mg/m 2 / day) for 5 days per week during 5 weeks or as oral preparations. Surgery was planned 6 8 weeks following the completion of preoperative therapy but was changed according to bed availability on the surgical ward. Routine postoperative follow-up of patients included physical examination and serum carcinoembryonic antigen every 3 4 months in the first 2 years after surgery and then every 6 months. Colonoscopy was performed a year after surgery and if normal every 3 years thereafter. CT of the chest, abdomen, and pelvis was done yearly in the first 2 years of follow-up. Survival was considered the interval between surgery and last follow-up or death (OS) or the date of last follow-up or recurrence (DFS). Patterns of disease recurrence (local and/or distant), DFS, and OS were analyzed. All the selected study parameters were compared between the groups. The institutional Helsinki Committee approved this study. Statistical Analysis Clinical and demographic data were entered into an Excel database using Microsoft Office software (Microsoft, WA). Continuous parameters were presented as medians and ranges or means and standard deviations. The patients were divided into two groups according to neoadjuvant surgery intervals (intervals of 7 weeks and [7 weeks). Comparisons between these groups of patients with regard to demographics, surgical parameters, and the various outcome variables were performed using independent samples t- tests, Mann Whitney, chi-square and Fisher s exact tests, as applicable. Pairwise comparisons between patient groups were done using the Gabriel and Games Howell multiple comparison tests. Comparisons between the groups with regard to OS and DFS were done by the log-rank test and were demonstrated by Kaplan Meier curves. Statistical significance was set at 0.05, and the SPSS for Windows software (Chicago, IL), Version 13.0 was used for the analysis. RESULTS A total of 132 patients who had locally advanced mid and low rectal cancer received neoadjuvant therapy followed by low anterior resection (LAR) or abdominoperineal resection (APR) with TME. There were 89 (67%) males and 43 females with a median age at operation of 64 years (range years). Abdominopelvic CT was performed on all patients prior to treatment, and 125 (95%)
3 EFFECT OF NEOADJUVANT-SURGERY INTERVAL TABLE 1. Demographics and clinical characteristics Interval 7 weeks (n = 48), n (%) Interval [7 weeks (n = 84), n (%) Mean age at operation (years) (P = 0.007) Gender (P = 0.31) Male Female Mean tumor distance from the anal verge (cm) (P = 0.46) EUS stage (utnm) (P = 0.27) Pathologic staging (ytnm) (P = 0.24) Preoperative radiation dose (P = 0.07) Postoperative chemotherapy (P = 0.63) 42 (87.5) 74 (86) Colorectal surgeon (P = 1.00) 44 (92) 76 (90) Median follow-up time (months) (P = 0.61) EUS, endorectal ultrasound. patients underwent EUS. Of these latter patients, 102 had ut3n0 disease and 23 had node positive disease (3 ut2n1, 20 ut3n1). EUS could not be performed in the other seven patients due to a bulky tumor. The neoadjuvant surgery interval ranged from 13 to 173 days (median 56 days). Almost all of the patients (n = 129, 98%) were operated at an interval of 4 17 weeks. There were 48 patients in group A and 84 in group B. Their demographic and clinical characteristics are outlined in Table 1. Group A patients were younger at operation (P = 0.007). The mean tumor distance from the anal verge, pre treatment EUS staging, postoperative pathologic staging by TNM classification, as well as the total cumulative delivered radiation dose, were comparable between the groups. Most of the patients (91%) were operated on by a colorectal surgeon, and there was no difference in the proportion of colorectal surgeons who performed the procedure between the groups. Type of surgery (LAR 62%), operative time (median 205 min), number of blood transfusions given during surgery (mean 0.8), length of hospital stay (median 9 days), and the use of diverting stoma in patients undergoing sphincter saving procedures were not influenced by the interval length (Table 2). There were no in hospital deaths. Minor and major complications were recorded in 53 (40%) patients (Table 3). Ten of the 82 patients (12%) who underwent a restorative operation (LAR) had anastomotic complications: four patients in group A and six in group B. Of these, two patients developed an anastomotic vaginal fistula and one an anastomotic leak that necessitated reoperation and diversion, and seven patients were treated conservatively with antibiotics. Of the 50 patients who underwent APR, three (6%) had a perineal wound infection and two had a pelvic abscess drained under CT guidance. Patients who were operated on after a neoadjuvant surgery interval 7 weeks had a complication rate of 48%, while only 36% of the patients operated on after an interval [7 weeks had complications (P = 0.17). Factors Predictive of Tumor Response to Neoadjuvant Therapy Thirty seven patients (28%) had pcr (n = 26) and near pcr (n = 11). The relationship between important predictors of outcomes (age at surgery, gender, tumor location, pre-treatment EUS staging, preoperative radiation dose, and neoadjuvant surgery time interval) and the rate of pcr and near pcr were examined using univariate and multivariate analysis. The only independent predictor of pcr and near pcr was neoadjuvant surgery time interval. The rate of pcr and near pcr increased with longer neoadjuvant surgery interval and was 17% in group A, and 35% in group B, a difference that was statistically significant (P = 0.03) (Fig. 1).
4 H. TULCHINSKY ET AL. TABLE 2. The effect of neoadjuvant surgery interval P value 7 weeks (n = 48), n (%) [7 weeks (n = 84), n (%) Operation type APR/LAR /30 32/52 Complications (48) 30 (36) Blood transfusions (40) 40 (48) Diverting ileostomy (46) 39 (46) Mean length of stay (days) Mean operation time (min) APR, abdominoperineal resection; LAR, low anterior resection. TABLE 3. Postoperative complications Number of patients Treatment Minor Wound Infection: Abdominal 4 Drainage Perineal 3 Drainage Colostomy 1 Drainage Dehiscence 2 Conservative Fever Phlebitis 6 IV line excision Port a cath infection 3 Excision Atelectasis 3 Physiotherapy Gastrointestinal SBO 1 Conservative Prolonged ileus 3 Conservative Urinary Infection 2 Antibiotics Retention 3 Catheterization Others 6 Major Anastomosis related Leak 7 Antibiotics 1 Diverting loop ileostomy Vaginal fistula 2 Diverting loop ileostomy Pelvic abscess post APR 2 Percutaneous drainage DVT 2 Anticoagulation PE 2 Anticoagulation SBO, small bowel obstruction; APR, abdominoperineal resection; DVT, deep vein thrombosis; PE, pulmonary embolism; IV, intravenous. Factors Prognostic for Disease-free and Overall Survival The median follow up period was 33 months (range 6 80 months) and it was similar for the two groups. A total of 23 patients (17%) had disease recurrence, of which 13 patients (two thirds) were from group A (P = 0.03). Fifteen patients died, again two thirds were from group A (P = 0.04). Table 4 summarizes the patterns and rates of disease recurrence and death rates according to interval groups. The effect of potential prognostic factors for DFS (age at surgery, gender, tumor location, pre-treatment EUS staging, preoperative radiation dose, surgical procedure, pathologic staging, postoperative chemotherapy, and neoadjuvant surgery time interval) was examined by univariate and multivariate analysis. The only independent prognostic factor was neoadjuvant surgery time interval. Figure 2 demonstrates the significantly improved DFS in patients operated on [7 weeks post neoadjuvant treatment (group B) compared with those operated on at an interval 7 weeks (group A) (P = 0.05). No difference in OS rates was observed between the groups (P = 0.07). Complete response (%) 40% 30% 20% 10% 0% Complete response according to interval groups 16.7% 34.5% <=7 Weeks (N=48) >7 Weeks (N=84) Interval Groups FIG. 1. Complete response rates according to interval groups (P = 0.03). DISCUSSION The standard surgical treatment of locally advanced low and mid rectal adenocarcinoma is LAR or APR with TME, according to tumor location. Surgical resection alone has high rates of locoregional failure. 9,10 Large clinical trials have demonstrated that preoperative chemoradiation reduces tumor size, increases the probability of tumor resectability and allows sphincter saving surgery for patients who otherwise would have required permanent colostomy. 2,11 15 A decrease in local recurrence rates and improved survival have been reported. 4,16 19 Furthermore, neoadjuvant therapy may result in complete eradication of all viable tumor cells from the rectal wall
5 EFFECT OF NEOADJUVANT-SURGERY INTERVAL TABLE 4. Patterns of disease recurrence according to study groups No. of patients (%) Interval 7 weeks (n = 48) Interval [7 weeks (n = 84) P value Total (n = 132) Local recurrence 3 (6%) 3 (4%) (4.5%) Metastases 9 (19%) 5 (6%) (11%) Local recurrence and metastases All recurrences 13 (27%) 10 (12%) (17%) Deaths 9 (19%) 6 (7%) (11%) as well as from the mesorectum, representing pcr in this setting. As the use of preoperative therapy broadens, it becomes more important to establish the optimal neoadjuvant surgery interval to achieve cure in the greatest number of patients. Sphincter saving procedures were possible in about two-thirds of our study patients (62%), a rate that correlates with that reported in other series in which neoadjuvant therapy was used. 2,20,21 The length of the neoadjuvant surgery interval had no influence on the rate of sphincter saving procedures, confirming the findings of other studies. 5,6,8 Our postoperative complication rate of 40% can be partially attributed to the fact that we included all grade 1 4 complications (according to Clevian et al. s classification 22 ) and, to some extent, to neoadjuvant therapy. These rates are in concordance with other series reporting on patients with rectal cancer who were operated on after neoadjuvant therapy. 21,23 A French prospective multicentric study published by Alves et al. 21 reported 43% morbidity following resection of mid and low rectal cancers. Whether preoperative radiation places additional risk on a low anastomosis after TME has been the subject of some debate. Several studies demonstrated a greater number of postoperative complications in patients treated by neoadjuvant chemoradiation. 18,24 26 For example, Buie et al. 24 showed that the addition of neoadjuvant chemoradiation to mesorectal excision increased the rate of pelvic sepsis threefold. In contrast, other studies showed no significant increase in postoperative complications. 23,27,28 Anastomotic dehiscence is the most serious early complication following a coloanal or low colorectal anastomosis. Our anastomotic leak rate of 12% correlates well with the incidence reported in previous large series (10 20%). 1,7,24,26,29,30 We could not demonstrate any difference in the rate of anastomotic complications between the groups, but the numbers of events were small. The Lyon R90-01 trial 5 randomized patients into two groups: patients in the short interval group were operated within 2 weeks after completion of radiotherapy and those in the long interval group at 6 8 weeks. The authors found no significant difference in the incidence of anastomotic complications between the groups (18% and 17%, respectively). We retrospectively examined different neoadjuvant surgery intervals for two main reasons: (1) to assess the influence on postoperative complications and mortality and (2) to determine whether we achieved higher rates of pcr and improved survival with longer intervals. Our findings showed decrease in the rate of overall morbidity in patients operated on after an interval [7 weeks but it did not reach statistical significance (36% versus 48%). Moore et al. 8 stratified 155 patients by median neoadjuvant surgery interval into those with a short interval ( 44 days) and those with a long interval ([44 days). Unlike our current findings, they observed a trend toward prolonged postoperative hospital stay in the long interval group (10 versus 8 days). Overall morbidity was similar between their groups, but anastomotic complications were more frequent in the long interval group (7% versus 0%). Stein et al. 6 divided 33 patients into two groups according to the time interval between completion of chemoradiation and surgical resection: 19 patients had an interval of 4 8 weeks (group A) and 14 patients had a time interval of weeks (group B). Three patients in their group A had anastomotic leaks and two underwent reoperation. None of the patients in their group B had leaks. The overall perioperative morbidity (27%) was not statistically different between their two groups. The pcr rate of 20% in the present study compares favorably with previous studies. 3,31 33 We observed a statistically significant increased rate of pcr and near pcr in patients operated on after an interval [7 weeks (group B) compared to those operated on after an interval 7 weeks (group A) (35% versus 17%, respectively). In the Lyon randomized trial, 5 Francois et al. showed that patients in the long interval group had either a pcr or a few residual cells more often than patients in the short interval group (26% versus 10%, respectively; P = ). Moore et al. 8 also demonstrated a trend toward an increased pcr rate with increasing the
6 H. TULCHINSKY ET AL. FIG. 2. Kaplan Meier estimation of the disease free survival. Comparison between patients operated after a neoadjuvant-surgery interval of 7 weeks and [7 weeks (P = 0.05, log rank test). prognostic factor for better DFS (P = 0.89). Thus, the better DFS of patients operated at an interval [7 weeks cannot be attributed to older age. Our results support the hypothesis that pcr is a favorable prognostic factor for improved local recurrence and DFS. It may represent a subgroup of rectal cancers with better biological behavior. Theodoropoulos et al. 34 reviewed 88 patients with ut3, T4 low and mid rectal cancers. Those with a pcr were characterized by significantly better DFS rates (P = 0.04), and the overall 5-year survival of patients with a pcr was 100% compared with 82.5% for patients without a pcr (P = 0.08). Garcia-Aguilar et al. 35 found a DFS of 95.2% for 21 patients with a pcr versus 55.4% for 140 patients without a pcr (P = 0.03). Kaminsky-Forrett et al. 36 evaluated the prognostic value of tumor downstaging and showed that the 3 and 5-year cancer specific survival rates were 100% for ypt0n0 and ypt2n0, 89% and 68% for ypt3n0, and 64% and 0% for ypt2t3n1. CONCLUSION neoadjuvant surgery interval, but their figures did not reach statistical significance. Conversely, Stein et al. 6 reported no significant difference in the rate of pcr when patients operated on after an interval of 4 8 weeks were compared to those operated on at an interval of weeks. Data on the impact of different neoadjuvant surgery intervals on long term disease recurrence and survival are limited. We were able to demonstrate better DFS rates in patients operated on at least 7 weeks after completion of neoadjuvant therapy. There were no differences in OS. In contrast, the long-term results of the Lyon R90 01 randomized study, 7 with a median follow up of 6.3 years showed no differences in local relapse and survival between the short and long interval groups. There are two important issues to address. The first is the potential drawback of this study due to its retrospective nature, but given the paucity of prospectively collected data, we believe that the results of this study are of value. The second is the homogeneity of the two groups. Comparisons between the two groups of patients with regard to demographics, clinical characteristics, and operative data revealed that they were similar and comparable in all parameters except for age at operation. Patients operated at an interval [7 weeks were older at operation (P = 0.007). We were able to show that age at operation was not a predictor for pcr and near pcr (P = 0.57) and not a The findings of the current study suggest that a neoadjuvant-surgery interval [7 weeks may be associated with improved rates of pcr and near pcr, decreased disease recurrence, and improved DFS. Prospective randomized trials are required to examine the optimal time interval that is needed to achieve minimum morbidity, maximal tumor downstaging, and minimum disease recurrence. ACKNOWLEDGEMENT Esther Eshkol is thanked for editorial assistance. REFERENCES 1. Chari RS, Tyler DS, Anscher MS, et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 1995; 221: Janjan NA, Khoo VS, Abbruzzese J, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999; 44: Read TE, McNevin MS, Gross EK, et al. Neoadjuvant therapy for adenocarcinoma of the rectum: tumor response and acute toxicity. Dis Colon Rectum 2001; 44: Sauer R, Becker H, Hohenberger W, et al. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on
7 EFFECT OF NEOADJUVANT-SURGERY INTERVAL downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: Stein DE, Mahmoud NN, Anne PR, et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 2003; 46: Glehen O, Chapet O, Adham M, et al. Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer. Br J Surg 2003; 90: Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004; 47: Bleday R, Wong WD. Recent advances in surgery for colon and rectal cancer. Curr Prob Cancer 1993; 17: Rich T, Gunderson LL, Lew R, et al. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983; 52: Chen ET, Mohiuddin M, Brodovsky H, et al. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys 1994; 30: Minsky BD, Cohen AM, Kemeny N, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992; 10: Rouanet P, Fabre JM, Dubois JB, et al. Conservative surgery for low rectal carcinoma after high-dose radiation. Functional and oncologic results. Ann Surg 1995; 221: Minsky BD, Cohen AM, Enker WE, et al. Sphincter preservation with preoperative radiation therapy and coloanal anastomosis. Int J Radiat Oncol Biol Phys 1995; 31: Vauthey JN, Marsh RW, Zlotecki RA, et al. Recent advances in the treatment and outcome of locally advanced rectal cancer. Ann Surg 1999; 229: Pucciarelli S, Friso ML, Toppan P, et al. Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: preliminary results. Ann Surg Oncol 2000; 7: Swedish Rectal Cancer Trial Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 2000; 284: Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: Valentini V, Coco C, Cellini N, et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys 1998; 40: Alves A, Panis Y, Mathieu P, et al. The Association Francaise de Chirurgie (AFC). Mortality and morbidity after surgery of mid and low rectal cancer. Results of a French prospective multicentric study. Gastroenterol Clin Biol 2005; 29: Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery 1992; 111: Valero G, Lujan JA, Hernandez Q, et al. Neoadjuvant radiation and chemotherapy in rectal cancer does not increase postoperative complications. Int J Colorectal Dis 2003; 18: Buie WD, MacLean AR, Attard JA, et al. Neoadjuvant chemoradiation increases the risk of pelvic sepsis after radical excision of rectal cancer. Dis Colon Rectum 2005; 48: Colorectal Cancer Collaborative Group Adjuvant radiotherapy for rectal cancer: a systemic overview of 8,507 patients from 22 randomised trials. Lancet 2001; 358: Matthiessen P, Hallbook O, Andersson M, et al. Risk factors for anastomotic leakage after anterior resection of the rectum. Colorectal Dis 2004; 6: Pucciarelli S, Toppan P, Friso ML, et al. Preoperative combined radiotherapy and chemotherapy for rectal cancer does not affect early postoperative morbidity and mortality in low anterior resection. Dis Colon Rectum 1999; 42: Shumate CR, Rich TA, Skibber JM, et al. Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. Cancer 1993; 71: Alberts JC, Parvaiz A, Moran BJ. Predicting risk and diminishing the consequences of anastomotic dehiscence following rectal resection. Colorectal Dis 2003; 5: Rullier E, Laurent C, Garrelon JL, et al. Risk factors for anastomotic leakage after resection of rectal cancer. Br J Surg 1998; 85: Burke SJ, Percarpio BA, Knight DC, et al. Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma. J Am Coll Surg 1998; 187: Mohiuddin M, Regine WF, John WJ, et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys 2000; 46: Mehta VK, Poen J, Ford J, et al. Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Dis Colon Rectum 2001; 44: Theodoropoulos G, Wise WE, Padmanabhan A, et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002; 45: Garcia-Aguilar J, de Hernandez Anda E, Sirivongs P, et al. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 2003; 46: Kaminsky-Forrett MC, Conroy T, Luporsi E, et al. Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys 1998; 42:
1. Background. increased sphincter preservation rate. Nonetheless, the 5- year disease-free survival and overall survival rates were
Gastroenterology Research and Practice Volume 2016, Article ID 7870815, 5 pages http://dx.doi.org/10.1155/2016/7870815 Research Article Does Extending the Waiting Time of Low-Rectal Cancer Surgery after
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationNeoadjuvant Therapy for Rectal Cancer is Overrated. Joon H. Lee, Research Resident University of Colorado 8/31/2009
Neoadjuvant Therapy for Rectal Cancer is Overrated Joon H. Lee, Research Resident University of Colorado 8/31/2009 Objectives Brief overview of staging rectal cancer Current guidelines for evaluation and
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationRectal Cancer: Classic Hits
Rectal Cancer: Classic Hits Charles M. Friel, MD Associate Professor of Surgery Section of Colon and Rectal Surgery University of Virginia September 28, 2016 None Disclosures 1 Objectives Review the Classic
More informationPre-operative Chemoradiotherapy with Oral Capecitabine in Locally Advanced, Resectable Rectal Cancer
Pre-operative Chemoradiotherapy with Oral Capecitabine in Locally Advanced, Resectable Rectal Cancer DIMITRIS P. KORKOLIS 1, CHRISTOS S. BOSKOS 2, GEORGE D. PLATANIOTIS 1, EMMANUEL GONTIKAKIS 1, IOANNIS
More informationEarly Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh
Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh What is Early rectal cancer? pt1t2n0m0 Predictors for LN involvement Size Depth Intramural
More informationLong Term Outcomes of Preoperative versus
RESEARCH ARTICLE Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand Pichayada Darunikorn
More informationShort course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided?
Short communication Short course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided? Michael A. Cummings 1, Kenneth Y. Usuki 1, Fergal J. Fleming 2, Mohamedtaki A. Tejani
More informationCOLON AND RECTAL CANCER
COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal
More informationFourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study
Original Article Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study Sezer Saglam 1, Dursun Bugra 2, Esra K. Saglam 3, Oktar Asoglu 4, Emre
More informationPreoperative capecitabine and pelvic radiation in locally advanced rectal cancer: preliminary results (Mansoura experience)
Original Article Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer: preliminary results (Mansoura experience) Abeer Hussien Anter 1, Ghada Ezzat Eladawei 2, Mahmoud Mosbah
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationCOLON AND RECTAL CANCER
No disclosures COLON AND RECTAL CANCER Mark Sun, MD Clinical Assistant Professor of Surgery University of Minnesota Colon and Rectal Cancer Statistics Overall Incidence 2016 134,490 new cases 8.0% of all
More informationState-of-the-art of surgery for resectable primary tumors
Early colorectal cancer State-of-the-art of surgery for resectable primary tumors (Special focus on rectal cancer surgery) Stefan Heinrich & Hauke Lang Department of General, Visceral and University Hospital
More informationIs stapled ileal pouch anal anastomosis a safe option in ulcerative colitis patients with dysplasia or cancer?
DOI 10.1007/s00384-009-0744-9 ORIGINAL ARTICLE Is stapled ileal pouch anal anastomosis a safe option in ulcerative colitis patients with dysplasia or cancer? O. Zmora & D. Spector & I. Dotan & J. M. Klausner
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationRe-irradiation in recurrent rectal cancer: single institution experience
Original Article Re-irradiation in recurrent rectal cancer: single institution experience Rasha Mohammad Abdel Latif, Ghada E. El-Adawei, Wael El-Sada Clinical Oncology & Nuclear Medicine Department, Mansoura
More informationPreoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer
Evidence-Based Series 2-4 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Preoperative or Postoperative Therapy for the Management of Patients with
More informationRECTAL CANCER CLINICAL CASE PRESENTATION
RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationUCL. Rectum Adenocarcinoma. Quality of conformal radiotherapy Impact for the surgeon P. Scalliet & K. Haustermans
Rectum Adenocarcinoma Quality of conformal radiotherapy Impact for the surgeon P. Scalliet & K. Haustermans Fifth Belgian Surgical Week May 6th, 2004, Oostende SOR rectum adenocarcinoma Indication of radiotherapy
More informationLaparoscopic Resection Of Colon & Rectal Cancers. R Sim Centre for Advanced Laparoscopic Surgery, TTSH
Laparoscopic Resection Of Colon & Rectal Cancers R Sim Centre for Advanced Laparoscopic Surgery, TTSH Feasibility and safety Adequacy - same radical surgery as open op. Efficacy short term benefits and
More informationDistal Margin Requirements After Preoperative Chemoradiotherapy for Distal Rectal Carcinomas: Are 1cm Distal Margins Sufficient?
Annals of Surgical Oncology, 8(2):163 169 Published by Lippincott Williams & Wilkins 2001 The Society of Surgical Oncology, Inc. Distal Margin Requirements After Preoperative Chemoradiotherapy for Distal
More informationDepartment of Radiotherapy, Pt. BDS PGIMS, Rohtak, Haryana, India
Bharti et al., IJPSR, 2010; Vol. 1 (11): 169-173 ISSN: 0975-8232 IJPSR (2010), Vol. 1, Issue 11 (Research Article) Received on 29 September, 2010; received in revised form 21 October, 2010; accepted 26
More informationComparison of Loop Ileostomy and Loop Colostomy as Defunctioning Stoma in Low Rectal Cancer Surgery NCI Experience
Kasr El Aini Journal of Surgery VOL., 12, NO 1 January 2011 75 Comparison of Loop Ileostomy and Loop Colostomy as Defunctioning Stoma in Low Rectal Cancer Surgery NCI Experience Ahmed Abbas, MD MRCS General
More informationRectal Cancer. Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco
Rectal Cancer Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco Modern Treatment for Rectal Cancer Improve Local Control Improved
More informationRectal Cancer. GI Practice Guideline
Rectal Cancer GI Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Dr. Francisco Perera MD, FRCPC (Radiation Oncologist) Dr. Jay Engel MD, FRCPC (Surgical Oncologist) Approval Date: 2006 This guideline
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of preoperative high dose rate brachytherapy for rectal cancer Rectal cancer is a
More informationInnovations in rectal cancer surgery TAMIS and transanal TME
Innovations in rectal cancer surgery TAMIS and transanal TME A.D Hoore MD PhD, EBSQ CR Chair Departement of Abdominal Surgery University Hospitals Leuven, Belgium Actual treatment in rectal Early rectal
More informationOutcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study
Original Article Outcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study Elmer E. van Eeghen 1, Frank den Boer 2, Sandra D. Bakker 1,
More informationChemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer Emily Chan, Qian Shi, Julio Garcia-Aguilar, Peter Cataldo, Jorge
More informationCase Report 17-Week Delay Surgery after Chemoradiation in Rectal Cancer with Complete Pathological Response
Case Reports in Surgery Volume 2015, Article ID 816491, 5 pages http://dx.doi.org/10.1155/2015/816491 Case Report 17-Week Delay Surgery after Chemoradiation in Rectal Cancer with Complete Pathological
More informationNOVA SCOTIA RECTAL CANCER PROJECT: A POPULATION-BASED ASSESSMENT OF RECTAL CANCER CARE AND OUTCOMES. Devon Paula Richardson
NOVA SCOTIA RECTAL CANCER PROJECT: A POPULATION-BASED ASSESSMENT OF RECTAL CANCER CARE AND OUTCOMES by Devon Paula Richardson Submitted in partial fulfilment of the requirements for the degree of Master
More informationRadiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationA Review of Rectal Cancer. Tim Geiger, MD Assistant Professor of Surgery, Colon and Rectal Surgery Vanderbilt University Medical Center
A Review of Rectal Cancer Tim Geiger, MD Assistant Professor of Surgery, Colon and Rectal Surgery Vanderbilt University Medical Center No disclosures Disclosures About me.. Grew up in Southern Illinois
More informationThe effect of rectal washout on local recurrence following rectal cancer surgery
COLORECTAL SURGERY Ann R Coll Surg Engl 208; 00: 46 5 doi 0.308/rcsann.207.0202 The effect of rectal washout on local recurrence following rectal cancer surgery SR Moosvi, K Manley, J Hernon Norfolk and
More informationPreoperative adjuvant radiotherapy
Preoperative adjuvant radiotherapy Dr John Hay Radiation Oncology Program BC Cancer Agency Vancouver Cancer Centre The key question for the surgeon Do you think that this tumour can be resected with clear
More informationRisk Factors of Permanent Stomas in Patients with Rectal Cancer after Low Anterior Resection with Temporary Stomas
Original Article http://dx.doi.org/10.3349/ymj.2015.56.2.447 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 56(2):447-453, 2015 Risk Factors of Permanent Stomas in Patients with Rectal Cancer after Low
More informationSphincter Sparing Procedures: Is it a standard for Management of Low Rectal Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 16, No. 4, December: 210-215, 2004 Sphincter Sparing Procedures: Is it a standard for Management of Low Rectal Cancer EL-SAYED ASHRAF KHALIL, M.D.FRCS; MOHAMAD
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationNeoadjuvant therapy of rectal carcinoma with UFT leucovorin plus radiotherapy
Original article Annals of Oncology 13: 730 736, 2002 DOI: 10.1093/annonc/mdf116 Neoadjuvant therapy of rectal carcinoma with UFT leucovorin plus radiotherapy J. Feliu 1 *, J. Calvillo 2, A. Escribano
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/22038 holds various files of this Leiden University dissertation. Author: Swellengrebel, H.A.M. Title: Challenges in the multimodality treatment of rectal
More informationMeta analysis in Rectal Cancer
Meta analysis in Rectal Cancer Dr. Monica Irukulla Professor and Head Department of Radiation Oncology Nizam s Institute of Medical Sciences hyderabad Areas of meta analysis in rectal cancers Epidemiology
More informationPROCARE FINAL FEEDBACK Definitions
1 PROCARE FINAL FEEDBACK 2006-2014 Definitions Version 0.2 29/10/2015 2 Table of Contents Introduction... 3 Part 1: PROCARE indicators 2006-2014... 4 1.1. Methods... 4 1.1.1. Descriptive numbers... 4 1.1.2.
More informationDifferential lymph node retrieval in rectal cancer: associated factors and effect on survival
Original Article Differential lymph node retrieval in rectal cancer: associated factors and effect on survival Cedrek McFadden 1, Brian McKinley 1, Brian Greenwell 2, Kaylee Knuckolls 1, Patrick Culumovic
More informationRectal Cancer : Curative treatment without surgery
Rectal Cancer : Curative treatment without surgery Dieter Hahnloser dieter.hahnloser@chuv.ch CHUV University Hospital Lausanne Switzerland Reasons for intervention (surgery) Cure Live longer Feel better
More informationRectal Cancer Update 2008 The Last 5 cm. Consensus Building
Rectal Cancer Update 2008 The Last 5 cm Consensus Building Case Distal Rectal Cancer 65 male physician Rectal mass: 5cm from anal verge, 1cm above sphincter? Imaging choice: CT vs MR vs ERUS? Adjuvant
More informationBackground: Patients and methods: Results: Conclusions:
Chapter 7 7 Results of European pooled analysis of IORT containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastase
More informationColorectal Surgery. Patient Care. Goals and Objectives
Colorectal Surgery Patient Care 1) Interpret the results of clinical evaluations (history, physical examination) performed on patients with a) Hemorrhoids b) Perianal abscess/fistula c) Anal fissure d)
More informationLaparoscopic vs Robotic Rectal Cancer Surgery: Making it better!
Laparoscopic vs Robotic Rectal Cancer Surgery: Making it better! Francis Seow- Choen Medical Director Seow-Choen Colorectal Centre Singapore In all situations: We have to use the right tool for the job
More informationCOLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
More informationGuidelines for Laparoscopic Resection of Curable Colon and Rectal Cancer
SAGES Society of American Gastrointestinal and Endoscopic Surgeons http://www.sages.org Guidelines for Laparoscopic Resection of Curable Colon and Rectal Cancer Author : SAGES Webmaster PREAMBLE The following
More informationThe impact of operation center and the prognostic factors on the outcome of patients with stage II and stage III colorectal cancer
Turkish Journal of Cancer Volume 38, No. 4, 28 175 The impact of operation center and the prognostic factors on the outcome of patients with stage II and stage III colorectal cancer ABDULLAH BÜYÜKÇELİK
More informationDelayed anastomotic leakage following laparoscopic intersphincteric resection for lower rectal cancer: report of four cases and literature review
Iwamoto et al. World Journal of Surgical Oncology (2017) 15:143 DOI 10.1186/s12957-017-1208-2 CASE REPORT Open Access Delayed anastomotic leakage following laparoscopic intersphincteric resection for lower
More informationThe Laparoscopic Approach in the Treatment of Distal Colorectal Cancer
The Open Colorectal Cancer Journal, 2011, 4, 13-17 13 Open Access The Laparoscopic Approach in the Treatment of Distal Colorectal Cancer Alexander Lebedyev 1, Damien Urban 2, Danny Rosin 1, Amram Ayalon
More informationPROCARE FINAL FEEDBACK
1 PROCARE FINAL FEEDBACK General report 2006-2014 Version 2.1 08/12/2015 PROCARE indicators 2006-2014... 3 Demographic Data... 3 Diagnosis and staging... 4 Time to first treatment... 6 Neoadjuvant treatment...
More informationTreatment of Locally Advanced Rectal Cancer: Current Concepts
Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationAnastomotic Leakage Following Low Anterior Resection of Rectal Cancer Considering the Role of Protective Stoma
Anastomotic Leakage Following Low Anterior Resection of Rectal Cancer Considering the Role of Protective Stoma Mozafar M 1, Sobhiyeh MR 1, Heibatollahi M 2 Original Article Abstract Background and aims:
More informationEvaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer
Efficacy of Modified De Gramont and FOLFOX4 Regimens for Locally Advanced Rectal Cancer RESEARCH COMMUNICATION Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant
More informationThe role of neoadjuvant radiotherapy for locally-advanced rectal cancer with resectable synchronous metastasis
Original Article The role of neoadjuvant radiotherapy for locally-advanced rectal cancer with resectable synchronous metastasis Croix C. Fossum 1, Jasim Y. Alabbad 2, Lindsay B. Romak 3, Christopher L.
More informationRadiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre
Radiotherapy for Rectal Cancer Kevin Palumbo Adelaide Radiotherapy Centre Overview CRC are common (3 rd commonest cancer) rectal Ca approx 25-30% of all CRC. Presentation PR bleeding: beware attributing
More informationMotility Disorders. Pelvic Floor. Colorectal Center for Functional Bowel Disorders (N = 701) January 2010 November 2011
Motility Disorders Pelvic Floor Colorectal Center for Functional Bowel Disorders (N = 71) January 21 November 211 New Patients 35 3 25 2 15 1 5 Constipation Fecal Incontinence Rectal Prolapse Digestive-Genital
More informationInnovations in Rectal Cancer Surgery
Innovations in Rectal Cancer Surgery A. D Hoore MD PhD, EBSQ-CR, (hon)fascrs A. Wolthuis MD PhD, EBSQ-CR, FACS G. Bislenghi MD Departement of Abdominal Surgery University Hospitals Leuven, Belgium invasiveness
More informationTreatment Interval between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer Patients: A Population-Based Study
Ann Surg Oncol (2016) 23:3593 3601 DOI 10.1245/s10434-016-5294-0 ORIGINAL ARTICLE COLORECTAL CANCER Treatment Interval between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer Patients: A Population-Based
More informationWorld Journal of Colorectal Surgery
World Journal of Colorectal Surgery Volume 3, Issue 4 2013 Article 3 Sigmoidorectal Intussusception Presenting as Prolapse Per Anus in an Adult Venugopal Hg Hasmukh B. Vora Mahendra S. Bhavsar SMT.NHL
More informationDoes the Timing of Esophagectomy After Chemoradiation Affect Outcome?
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationClinical Study Prognostic Value of Mandard and Dworak Tumor Regression Grading in Rectal Cancer: Study of a Single Tertiary Center
ISRN Surgery, Article ID 310542, 8 pages http://dx.doi.org/10.1155/2014/310542 Clinical Study Prognostic Value of Mandard and Dworak Tumor Regression Grading in Rectal Cancer: Study of a Single Tertiary
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection A pooled analysis of 3,313 patients Monique
More informationManagement of Perforated Colon Cancers
Management of Perforated Colon Cancers Introduction Colon and rectal cancers are the most common gastrointestinal cancers. They are 3 rd most common and 2 nd most common causes of cancer deaths among men
More informationCurrent Issues and Controversies in the Management of Rectal Cancer
Current Issues and Controversies in the Management of Rectal Cancer Ghazi M. Nsouli MD 11 th Annual Congress of the Lebanese Society of Gastroenterology November 16, 2012 GMN 20121116 1 Staging of rectal
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationTemporary Diverting Stoma Improves Recovery of Anastomotic Leakage after Anterior Resection for Rectal Cancer
www.nature.com/scientificreports Received: 5 April 2017 Accepted: 7 November 2017 Published: xx xx xxxx OPEN Temporary Diverting Stoma Improves Recovery of Anastomotic Leakage after Anterior Resection
More informationManagement of colorectal anastomotic leakage: differences between salvage and anastomotic takedown
The American Journal of Surgery (2012) 204, 671 676 Clinical Science Management of colorectal anastomotic leakage: differences between salvage and anastomotic takedown Domenico Fraccalvieri, M.D., Sebastiano
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationCOLORECTAL CANCER STAGING in 2010
COLORECTAL CANCER STAGING in 2010 Robert A. Halvorsen, MD, FACR MCV Hospitals / VCU Medical Center Richmond, Virginia I do not have any relevant financial relationships with any commercial interests COLON
More informationAdjuvant and neoadjuvant chemotherapy for rectal cancer: Expensive but little gain
Adjuvant and neoadjuvant chemotherapy for rectal cancer: Expensive but little gain Outline The problem Adjuvant therapy Neoadjuvant therapy Options Conclusion The problem 30 years ago: Local recurrence
More informationTransanal endoscopic microsurgery for early rectal cancer: single center experience
Original paper Videosurgery Transanal endoscopic microsurgery for early rectal cancer: single center experience Narimantas Samalavicius 1,2, Marijus Ambrazevicius 1, Alfredas Kilius 1, Kestutis Petrulis
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationMULTIDISCIPLINARY MANAGEMENT OF RECTAL CANCER A RETROSPECTIVE STUDY
MULTIDISCIPLINARY MANAGEMENT OF RECTAL CANCER A RETROSPECTIVE STUDY V. Scripcariu 1, Elena Dajbog 1, I. Radu 1, C. Dragomir 1, D. Ferariu 2, I. Bild 3, Elena Albulescu 3, L. Miron 3 1 Third Surgical Clinic,
More informationLymph node harvest in rectal cancer surgery following neoadjuvant chemoradiotherapy
Journal of Surgery 2014; 2(2): 27-1 Published online April 10, 2014 (http://www.sciencepublishinggroup.com/j/js) doi: 10.1148/j.js.20140202.1 Lymph node harvest in rectal cancer surgery following neoadjuvant
More informationIs adjuvant radiotherapy warranted in resected pt1-2 node-positive rectal cancer?
Peng et al. Radiation Oncology 2013, 8:290 RESEARCH Open Access Is adjuvant radiotherapy warranted in resected pt1-2 node-positive rectal cancer? Junjie Peng 1,2, Xinxiang Li 1,2, Ying Ding 3, Debing Shi
More information8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank
Quiz 1 Overview 1. Beginning with the cecum, which is the correct sequence of colon subsites? a. Cecum, ascending, splenic flexure, transverse, hepatic flexure, descending, sigmoid. b. Cecum, ascending,
More informationCitation for published version (APA): Bartels, S. A. L. (2013). Laparoscopic colorectal surgery: beyond the short-term effects
UvA-DARE (Digital Academic Repository) Laparoscopic colorectal surgery: beyond the short-term effects Bartels, S.A.L. Link to publication Citation for published version (APA): Bartels, S. A. L. (2013).
More informationLYMPH NODE RATIO AS A PROGNOSTIC FACTOR IN PATIENTS WITH STAGE III RECTAL CANCER TREATED WITH TOTAL MESORECTAL EXCISION FOLLOWED BY CHEMORADIOTHERAPY
doi:10.1016/j.ijrobp.2008.08.065 Int. J. Radiation Oncology Biol. Phys., Vol. 74, No. 3, pp. 796 802, 2009 Copyright Ó 2009 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/09/$ see front
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominoperineal excision, of rectal cancer, 93 111 current controversies in, 106 109 extent of perineal dissection and removal of pelvic floor,
More informationColorectal Cancer Dashboard
Process Risk Assessment Presence or absence of cancer in first-degree blood relatives documented for patients with colorectal cancer Percent of patients with colorectal cancer for whom presence or absence
More informationStaging of cancer patients is an important tool for the selection
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:997 1003 Improvement of Staging by Combining Tumor and Treatment Parameters: The Value for Prognostication in Rectal Cancer MARLEEN J. E. M. GOSENS,* J.
More informationRECTAL CANCER: Adjuvant Therapy. Maury Rosenstein, MD Montefiore Medical Center December 2012
RECTAL CANCER: Adjuvant Therapy Maury Rosenstein, MD Montefiore Medical Center December 2012 Overview Indications for adjuvant therapy Preoperative Postoperative New Advances Epidemiology Approximately
More informationUniversity of Groningen. Colorectal Anastomoses Bakker, Ilsalien
University of Groningen Colorectal Anastomoses Bakker, Ilsalien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationIs Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer?
Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer? Lee H, Park JY, Youn S, Kwon W, Heo JS, Choi SH, Choi DW Department of Surgery, Samsung Medical Center Sungkyunkwan
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More information